18 January 2018 - - The Woodbury, New York-based pancreatic research funding organization Lustgarten Foundation funded USD 22m in 2017 as part of its commitment to invest USD 40m by the end of 2018, the Foundation said.
In addition to funding accomplished scientists in pancreatic cancer research, the Foundation is attracting new researchers to the field including David Sabatini, M.D., Ph.D., Whitehead Institute for Biomedical Research, and David Pellman, M.D., Dana-Farber Cancer Institute.
Lustgarten Foundation research investigators are charged with advancing the study of pancreatic cancer that will lead to earlier detection methods, personalized medicine, and new and effective therapies. Various approaches including immunotherapy, cancer genetics, epigenetics, and cancer metabolism will be used to achieve very specific outcomes.
Core to the Foundation's research strategy is funding a dedicated pancreatic cancer research laboratory at the Cold Spring Harbor Laboratory.
The Foundation's new Translational Clinical Program is funding programs at Columbia University Medical Center, Dana-Farber Cancer Institute, and the Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine with the goal of moving biology into the clinic.
The Lustgarten Foundation is a private foundation dedicated to funding pancreatic cancer research. The Foundation supports research to find a cure for pancreatic cancer, facilitates dialogue within the medical and scientific community, and educates the public about the disease through awareness campaigns and fundraising events. Since its inception, it has directed USD 154m to research.